PDS Biotech reports positive translational data for PDS0101 and PDS01ADC at SITC 2025

PDS Biotechnology Corp

Translational study of PDS0101 combo in 50 patients shows multiple serum biomarkers predict clinical benefit accurately.
PDS01ADC monotherapy increases NK cells with tumor-killing phenotypes and decreases poor-response NK cells in advanced solid tumors.
PDS01ADC increases self-replicating stem-like memory T cells (CD8 and CD4) associated with disease stabilization in 28 patients.
Data selected among top 150 abstracts at SITC; presented under NCI CRADA collaboration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.